Domperidone Dosing Recommendations
Domperidone is not approved for use in humans in the United States and should only be obtained through FDA investigational drug application, with recommended dosing of 10 mg three times daily, avoiding escalation beyond 30 mg/day due to significant cardiac safety concerns. 1, 2
FDA Status and Availability
Domperidone is explicitly not approved for any indication in humans in the US 1. In clinical practice, availability is restricted to FDA investigational drug applications only 2. This severely limits its use compared to other antiemetic and prokinetic agents.
Adult Dosing
Standard Dosing
- Starting dose: 10 mg three times daily (30 mg/day total) 2
- Maximum recommended dose: 30 mg/day 2, 3, 4
Higher Dose Considerations (Refractory Cases Only)
While escalation to 20 mg four times daily (80 mg/day) has been reported in refractory gastroparesis, this should probably be avoided for cardiovascular safety considerations 2. Research data shows:
- Doses >30 mg/day significantly increase cardiovascular event risk (OR: 3.14,95% CI 1.19-8.30) 3
- Mean highest doses of 80 mg/day (range 40-120 mg) were used in highly selected refractory patients with intensive cardiac monitoring 5
- At these higher doses, 9.5% experienced meaningful QTc prolongation 5
Pediatric Dosing
Current authorization restricts use to children ≥12 years for relief of nausea and vomiting only, for short-term use 6, 7.
- Adolescents 12-17 years: Domperidone can be used for nausea, though oral administration is unlikely to prevent vomiting 7
- Younger children: Use is off-label with limited efficacy data and controversial evidence 6
Critical Cardiac Safety Considerations
Mandatory Exclusion Criteria
Absolutely contraindicated in patients with:
- History of dangerous arrhythmias 5
- Prolonged QTc at baseline 5
- Clinically significant electrolyte disturbances 5
- Concurrent use of QT-prolonging medications 8, 9
Required Monitoring
For any patient receiving domperidone:
- Baseline ECG before initiation 5
- Frequent ECG monitoring during treatment as mandated by FDA 5
- Monitor for QTc prolongation (>450 ms males, >470 ms females) 5
- Assess for palpitations or chest pain 5
Dose-Response Cardiac Risk
The evidence demonstrates clear dose-dependent cardiac toxicity:
- ≤30 mg/day: No significant increase in CV event risk 3
- >30 mg/day: Significant increase in sudden cardiac death risk 3, 4
- Overall use: Increased odds ratio for sudden cardiac death of 2.8 (range 1.53-6.21) 10, 11
- Risk increases sharply above 30 mg/day 10
Special Populations
Pregnant and Lactating Women
- Pregnant women should use extreme caution when handling domperidone, as systemic exposure may affect reproductive hormones 1
- Safety in lactating women and nursing children has not been evaluated 1
- Consult physician for any exposure 1
Patients with Cardiac Risk Factors
Domperidone should be avoided entirely in patients ≥75 years or those with cardiovascular disease, given the narrow safety margin (safety index of only ~2.5, which is 12-fold below accepted minimum) 10, 12.
Clinical Context and Alternatives
Given the limited benefits (defined daily dose of 30 mg fails to show unequivocal gastrointestinal benefits beyond placebo) 10 and significant cardiac risks, alternative antiemetics should be strongly considered first:
- 5-HT3 antagonists (ondansetron, granisetron) for nausea/vomiting 2
- NK-1 receptor antagonists (aprepitant) for refractory nausea 2
- Metoclopramide (though domperidone has lower CV risk than metoclopramide: OR 0.63) 3
Key Pitfalls to Avoid
- Never exceed 30 mg/day without exceptional circumstances and intensive cardiac monitoring
- Screen for drug interactions with other QT-prolonging medications 8, 9
- Do not use in elderly patients with cardiovascular risk factors
- Verify proper indication - efficacy data in children is controversial and limited 6
- Ensure FDA investigational drug application is in place before prescribing in the US 2